What amount sold does MindImmune Therapeutics, Inc. report in Form D filings?

The latest linked filings report $21.3M sold across 3 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was MindImmune Therapeutics, Inc.'s most recent SEC filing?

MindImmune Therapeutics, Inc.'s most recent Form D filing was on 2026-03-05.

How many investors does MindImmune Therapeutics, Inc. have?

The most recent Form D filing lists 15 investor(s).

What type of securities does MindImmune Therapeutics, Inc. offer?

MindImmune Therapeutics, Inc.'s SEC Form D filings indicate equity offerings.

MindImmune Therapeutics, Inc.

CIK: 0001792522·Pharmaceuticals·KINGSTON, RI·Corporation

Reported Sold

$21,318,342

Total Filings

Identified Offerings

Last Filed

Mar 5, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Mar 5, 2026Form D/A — Amendment

Reported sold: $15,218,343 · Target: $17,014,485

Rule 506(b)·15 investors

Changed: Reported amount sold, Offering target, Reported investors, Sales commissions, Finders fees, Non-accredited investors

Dec 5, 2025Form D — New notice

Reported sold: $10,203,858 · Target: $12,000,000

Rule 506(b)·14 investors

Feb 4, 2022Form D — New notice

Reported sold: $5,349,999 · Target: $8,880,000

Rule 506(b)·12 investors

Nov 1, 2019Form D — New notice

Reported sold: $750,000 · Target: $3,000,000

Rule 506(b)·8 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

25%

Latest reported sold across 3 identified offerings

$21,318,342

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Christopher O'Donnell

Director

Appears on 3 filings

Bradley Margus

Director

Appears on 2 filings

Reetika Bhardwaj

Director

Appears on 2 filings

Isaac Stoner

Executive Officer, Director

Appears on 2 filings

Stevin Zorn

Related Person

Appears on 2 filings

Robert B. Nelson

Related Person

Appears on 2 filings

Diane Gooding

Related Person

Appears on 1 filing

Frank S. Menniti

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Mar 5, 2026	Amendment	$17,014,485	$15,218,343	15
Dec 5, 2025	New	$12,000,000	$10,203,858	14
Feb 4, 2022	New	$8,880,000	$5,349,999	12
Nov 1, 2019	New	$3,000,000	$750,000	8

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

EIKONOKLASTES THERAPEUTICS, INC.

Pharmaceuticals

Offering target: $18,638,880

Filed Oct 5, 2026